Home › NDC Lookup › Ingredients › Acetazolamide › 87448-1601-01
Acetazolamide 250 mg Tablet, 1 tablet — NDC 87448-1601-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Acetazolamide 250 mg Tablet, 1 tablet — NDC 87448-1601-1 (Billing 87448-1601-01)

by Northwestern Memorial HealthCare · 1 TABLET in 1 POUCH

This is a package of 1 tablet of Acetazolamide 250 mg Tablet from Northwestern Memorial HealthCare, no longer marketed (first marketed Nov 2020), no longer in the FDA NDC Directory. It is this product's only package size.

NDC 87448-1601-01
🏷️ FDA NDC (as labeled) 87448-1601-1 billing pads the package segment with a zero
Rx only Generic Discontinued Non-controlled ⚠ Inactivated by FDA ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 87448-1601-1 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
87448 labeler · 1601 product · 1 package
Package marketed since
Nov 13, 2020
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Barcode (UPC-A, from the NDC)
3 8744816011 5
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Acetazolamide (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · Aug 24, 2024 — Discoloration (Rubicon Research Private Limited) · FDA recall D-0659-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
⚠️
Excluded from the active FDA NDC Directory. FDA inactivated this product’s listing record, so it is excluded from the active NDC Directory. The listing was last certified through Dec 2027. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory. Search the FDA NDC Directory ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 87448-1601-1
Product NDC 87448-1601
11-digit billing NDC 87448160101
RxCUI 197304
UNII O3FX965V0I
Application # ANDA214282
SPL Set ID 4ef83f4e-d925-8b6a-e063-6294a90ad04c
Established class (EPC) Carbonic Anhydrase Inhibitor
Mechanism of action Carbonic Anhydrase Inhibitors
Chemical class Sulfonamides
DEA schedule Non-controlled
Marketing category ANDA
Marketing status Discontinued
FDA listing status Inactivated by FDA (certified through Dec 2027)
Marketing start 2020-11-13
Route ORAL
Dosage form TABLET
Substance ACETAZOLAMIDE
TE code (Orange Book) AB · RLD · RS
Quick answers
  • RxCUI (RxNorm): 197304
Why two NDCs? The FDA registers this code as 87448-1601-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 87448-1601-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Carbonic Anhydrase Inhibitor class.

Pharmacologic class Carbonic Anhydrase Inhibitor
Drug family (ATC) Carbonic anhydrase inhibitors
How it works Carbonic Anhydrase Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

📗 Our plain-language guide HelloPharmacist
  • It is used as an add-on treatment, most commonly for glaucoma. Depending on the product, it is also used for swelling from heart failure, certain seizure disorders, and preventing...
  • Tablets and capsules are taken by mouth, and the injection is given in a vein by a professional. Extended-release capsules for glaucoma are usually taken morning and evening. For m...
  • Tingling in fingers or face, more urination, tiredness, nausea, appetite or taste changes, and drowsiness are among the reported effects. Mention them if they bother you.
  • Call right away if you get a rash, blisters, fever, sore throat, unusual bruising, yellow skin or eyes, confusion, or swelling of the face. Acetazolamide is a sulfa-type drug, and...
📖 Read our full Acetazolamide guide →
8
Nutrient depletion considerations

Acetazolamide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Acetazolamide nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · Q2 2026 $0.2706 $0.27 / 1 tablet
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
87448-1601-01 You're viewing this Main listing 1 TABLET in 1 POUCH 2020-11-13 — Inactivated by FDA

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
acetazolamide 250 mg 00904-6663-61 Major 100 tablets $0.134 AB Availability likely —
acetazolamide 250 mg 23155-0288-01 Heritage 100 tablets $0.134 AB Availability likely —
Acetazolamide 250 mg 50268-0054-15 AvPAK 50 tablets $0.134 AB Availability likely —
Acetazolamide 250 mg 59651-0906-01 Aurobindo 100 tablets $0.134 AB Availability likely —
Acetazolamide 250 mg 62135-0608-12 Chartwell 120 tablets $0.134 AB Availability likely —
Acetazolamide 250 mg 64380-0834-06 Strides 100 tablets $0.134 AB Availability likely —
Acetazolamide 250 mg 70756-0721-11 Lifestar 100 tablets $0.134 AB Availability likely —
Acetazolamide 250 mg 71930-0009-12 Eywa 100 tablets $0.134 AB Availability likely —
acetaZOLAMIDE 250 mg 72578-0150-01 Viona 100 tablets $0.134 AB Availability likely —
Acetazolamide 250 mg 72888-0048-01 Advagen 100 tablets $0.134 AB Availability likely —
Acetazolamide 250 mg 10135-0831-01 Marlex 100 tablets — AB FDA listed —
Acetazolamide 250 mg 27241-0133-04 Ajanta 100 tablets — — FDA listed —
acetazolamide 250 mg 42291-0090-01 AvKARE 100 tablets — AB FDA listed —
Acetazolamide 250 mg 50090-5593-00 A-S 12 tablets — AB FDA listed —
acetaZOLAMIDE 250 mg 50090-7536-00 A-S 12 tablets — AB FDA listed —
Acetazolamide 250 mg 52817-0201-00 TRUPHARMA, 1000 tablets — AB FDA listed —
Acetazolamide 250 mg 63629-1195-01 Bryant 100 tablets — AB FDA listed —
acetaZOLAMIDE 250 mg 70710-1239-01 Zydus 100 tablets — AB FDA listed —
acetaZOLAMIDE 250 mg 70771-1828-01 Zydus 100 tablets — AB FDA listed —
Acetazolamide 250 mg 70954-0034-20 ANI 1000 tablets — AB FDA listed —
Acetazolamide 250 mg 71335-2215-01 Bryant 100 tablets — AB FDA listed —
Acetazolamide 250 mg 72162-1979-01 Bryant 100 tablets — AB FDA listed —
Acetazolamide 250 mg 72789-0237-01 PD-Rx 100 tablets — AB FDA listed —
Acetazolamide 250 mg 81005-0105-01 Aarkish 100 tablets — AB FDA listed —
Acetazolamide 250 mgthis 87448-1601-01 Northwestern 1 tablet — AB Discontinued —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
On the market since
Nov 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Acetazolamide inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

A current SPL was checked, but it does not contain a structured or narrative inactive-ingredient list for this product. This does not mean the product has no inactive ingredients.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerNorthwestern Memorial HealthCare
Application holderMANKIND PHARMA LTD
FDA applicationANDA214282 (ANDA)
Labeler code87448
First marketedNov 2020
Product typeHuman Prescription Drug
Portfolio5 products on file

More NDCs from Northwestern Memorial HealthCare labeler code 87448

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📦 How Supplied / Storage and Handling 📄 Package Label / Principal Display Panel
📦 How Supplied / Storage and Handling 88 words ▾

HOW SUPPLIED Acetazolamide tablets USP are supplied as follows: 250 mg - White color, round standard convex uncoated tablet, debossed "LS721" on one side and scored in quarters on another side. NDC 70756-721-11 - Bottle of 100 NDC 70756-721-99 - Unit-dose child-resistant blister pack of 100 (10 x 10) tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Dispense in tight, light-resistant container as defined in the USP using a child-resistant closure.

Keep this and all medication out of the reach of children.

📄 Package Label / Principal Display Panel 3 words ▾

Acetazolamide 250mg Tab

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Acetazolamide — the program that covers self-administered drugs. 12 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Acetazolamide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$2.17M
Claims incl. refills
65K
Beneficiaries
44.5K
Spend / beneficiary
$48.76
Spend / claim
$33.33
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Who lists this product with the FDA?
Northwestern Memorial HealthCare is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 87448-1502-03 · Northwestern 87448-1701-02 · Northwestern →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.